HFNO in Pneumonia Patients Presenting With Acute Hypoxemic Respiratory Failure (NCT05809089) | Clinical Trial Compass
CompletedNot Applicable
HFNO in Pneumonia Patients Presenting With Acute Hypoxemic Respiratory Failure
Egypt200 participantsStarted 2020-11-20
Plain-language summary
High-flow nasal oxygen (HFNO) therapy is an upcoming and beneficial modality for patients with acute hypoxemic respiratory failure (AHRF).
To evaluate whether early use of HFNO in pneumonia patients with (AHRF) can reduce the need for invasive ventilation.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pneumonia adults patients (age\>18 years) with AHRF were eligible for this study after conventional oxygen therapy failure.
* The criteria for diagnosing AHRF were defined as the presence of a respiratory rate (RR) more than 25 breaths/min with SpO2 less than 92%, and/or the arterial oxygen partial pressure (PaO2) to FiO2 ratio less than 300 mmHg while breathing oxygen delivered by a conventional venturi device at a fraction of inspiration oxygen of 0.5 (as per maximum for Venturi mask) administered for at least 60 minutes.
Exclusion criteria:
* Patients requiring emergency intubation,
* Recent esophageal, facial, or cranial trauma or surgery,
* Severely decreased consciousness (Glasgow coma scale \[GCS\] of 11 or less),
* Severe hemodynamic instability (patient on inotropic or vasopressor support), ° Severe ventricular arrhythmia or myocardial ischemia,
* Tracheotomy or other upper airway disorders,
* Active upper gastrointestinal bleeding, and
* Inability to clear respiratory secretions .